[Allergy to Pfizer-BioNTech® vaccine demonstrated by skin testing].

Q3 Medicine

Revista alergia Mexico Pub Date : 2023-01-04 DOI:10.29262/ram.v69i2.1088

Carlos David Estrada-García, Ana Paola Macías-Robles, Rosa María Cortés-Grimaldo, Hilda Lilian Carvajal-Alonso, Marlen Barreto-Alcalá, Adriana Ramírez-Nepomuceno, David Esparza-Amaya, Kareli Guadalupe Coronado-Hernández, Britza Barrios-Díaz, Héctor Hugo Campos-Téllez

{"title":"[Allergy to Pfizer-BioNTech® vaccine demonstrated by skin testing].","authors":"Carlos David Estrada-García, Ana Paola Macías-Robles, Rosa María Cortés-Grimaldo, Hilda Lilian Carvajal-Alonso, Marlen Barreto-Alcalá, Adriana Ramírez-Nepomuceno, David Esparza-Amaya, Kareli Guadalupe Coronado-Hernández, Britza Barrios-Díaz, Héctor Hugo Campos-Téllez","doi":"10.29262/ram.v69i2.1088","DOIUrl":null,"url":null,"abstract":"Background: The Pfizer-BioNTech® BNT162b2 vaccine, provides 95% effectiveness from the second dose onwards. The reported rate of anaphylaxis to COVID-19 vaccines is 4.7 cases/million doses administered.Case report: 30-year-old female, health professional, history of allergic rhinitis, asthma, reaction to eye cosmetics and adhesive tape: erythema, edema, and local pruritus. Immediately after application of the first dose of Pfizer-BioNTech vaccine, she presented grade III anaphylaxis. The patient was stratified, phenotyped and skin tests with PEG 3350 were positive. A recommendation was issued not to reapply vaccine containing polyethylene glycol and alternatives were offered.Conclusions: An adequate risk stratification should be performed before applying mRNA-based COVID-19 vaccines for the first time in at-risk groups. In case of anaphylaxis at the first dose, phenotyping and further study with PEG skin tests should be performed and vaccination alternatives should be offered.","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"69 2","pages":"89-92"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista alergia Mexico","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29262/ram.v69i2.1088","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The Pfizer-BioNTech® BNT162b2 vaccine, provides 95% effectiveness from the second dose onwards. The reported rate of anaphylaxis to COVID-19 vaccines is 4.7 cases/million doses administered.

Case report: 30-year-old female, health professional, history of allergic rhinitis, asthma, reaction to eye cosmetics and adhesive tape: erythema, edema, and local pruritus. Immediately after application of the first dose of Pfizer-BioNTech vaccine, she presented grade III anaphylaxis. The patient was stratified, phenotyped and skin tests with PEG 3350 were positive. A recommendation was issued not to reapply vaccine containing polyethylene glycol and alternatives were offered.

Conclusions: An adequate risk stratification should be performed before applying mRNA-based COVID-19 vaccines for the first time in at-risk groups. In case of anaphylaxis at the first dose, phenotyping and further study with PEG skin tests should be performed and vaccination alternatives should be offered.

查看原文本刊更多论文

[皮肤试验证明对辉瑞- biontech®疫苗过敏]。

背景:辉瑞- biontech®BNT162b2疫苗从第二剂开始提供95%的有效性。报告的COVID-19疫苗过敏反应率为4.7例/百万剂。病例报告:30岁女性，卫生专业人员，变应性鼻炎、哮喘病史，眼部化妆品及胶布反应:红斑、水肿、局部瘙痒。在使用第一剂辉瑞- biontech疫苗后，她立即出现了III级过敏反应。对患者进行分层，分型，PEG 3350皮肤试验呈阳性。建议不要重新使用含有聚乙二醇的疫苗，并提供了替代品。结论:高危人群首次接种基于mrna的COVID-19疫苗前应进行充分的风险分层。在首次给药时出现过敏反应的情况下，应进行表型分析和PEG皮肤试验的进一步研究，并提供替代疫苗接种。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊